Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00068250 | Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | completed | Phase 1 / Phase 2 | 60 | Radiation Therapy Oncology GroupNETWORK | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00766753 | Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 22 | Frank LiebermanOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00782756 | Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma | completed | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01632228 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | completed | Phase 2 | 135 | Hoffmann-La RocheINDUSTRY | 8 | Feb 5, 2018 | clinicaltrials |
| NCT00619112 | Temozolomide in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 60 | University of California, San FranciscoOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02971319 | Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma | completed | Phase 2 | 32 | Proactina S.A.OTHER | 2 | Jan 26, 2018 | clinicaltrials |
| NCT00003473 | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas | completed | Phase 2 | 20 | Burzynski Research InstituteOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00458601 | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme(ACT III) | completed | Phase 2 | 82 | Celldex TherapeuticsINDUSTRY | 1 | Jan 16, 2018 | clinicaltrials |
| NCT00387790 | Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jan 4, 2018 | clinicaltrials |
| NCT03388372 | Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma | completed | Phase 2 | 39 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT00895180 | Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 80 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 27, 2017 | clinicaltrials |
| NCT01753713 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 33 | Manmeet Ahluwalia, MDOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00362570 | Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | completed | Phase 2 | 1 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2017 | clinicaltrials |
| NCT02707549 | Fluid Therapy During Brain Tumor Resection in Children | completed | Phase 2 | 53 | Federal University of São PauloOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00396019 | Study of PEG-Intron for Plexiform Neurofibromas | completed | Phase 2 | 86 | University of PittsburghOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00405327 | A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation | completed | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00859040 | Monthly SOM230C for Recurrent or Progressive Meningioma | completed | Phase 2 | 34 | Patrick Y. Wen, MDOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01866449 | Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme | completed | Phase 2 | 24 | University of UlmOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT03090971 | Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 | completed | Phase 2 | 7 | Fundação Educacional Serra dos ÓrgãosOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT02301364 | Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
| NCT03310372 | Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme(TEMOFRAC) | completed | Phase 2 | 46 | Central Hospital, Nancy, FranceOTHER | 0 | Oct 17, 2017 | clinicaltrials |
| NCT01310868 | Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma | completed | Phase 2 | 59 | University College, LondonOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT00659984 | N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma | completed | Phase 2 | 15 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 4, 2017 | clinicaltrials |
| NCT00309907 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | completed | Phase 2 | 39 | Children's Oncology GroupNETWORK | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00187486 | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors | completed | Phase 2 | 66 | University of California, San FranciscoOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT00003460 | Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors(PNET) | completed | Phase 2 | 13 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003470 | Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma(AA) | completed | Phase 2 | 27 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003475 | Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003477 | Antineoplaston Therapy in Treating Children With Visual Pathway Glioma(VPG) | completed | Phase 2 | 12 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003537 | Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma(AA) | completed | Phase 2 | 19 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003457 | Antineoplaston Therapy in Treating Patients With Brain Tumors | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02852382 | The Effects of Scalp Block on Haemodynamic Response and Postoperative Pain in Posterior Fossa Surgery | completed | Phase 2 | 45 | Istanbul UniversityOTHER | 0 | Aug 22, 2017 | clinicaltrials |
| NCT02029573 | Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma(ART) | completed | Phase 2 | 36 | King Fahad Medical CityOTHER_GOV | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00980343 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00727506 | BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma | completed | Phase 2 | 151 | Boehringer IngelheimINDUSTRY | 2 | Aug 15, 2017 | clinicaltrials |
| NCT00540722 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01708174 | A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) | completed | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 13 | Aug 11, 2017 | clinicaltrials |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 59 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT00823797 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | completed | Phase 2 | 45 | University of WashingtonOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT00028106 | 131MIBG to Treat Malignant Pheochromocytoma | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01140360 | Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas(0908-09) | completed | Phase 1 / Phase 2 | 21 | Kent RobertsonOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01290263 | Amgen 386 for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00392171 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | completed | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00424554 | Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) | completed | Phase 2 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00684567 | Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) | completed | Phase 2 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Feb 7, 2018source: clinicaltrials